FOXM1 and neoplasm: To validate whether H3K79me2‐FOXM1 modulates tumor growth via alteration of the TME composition in vivo, we measured T cells from spleen including CD4+, CD8+, and regulatory T cell (Tregs) as well as BMDCs from EPZ‐ or Thiostrepton‐treated TBM by tail vein injections.